Press release


Biophytis announces ratio change under its American
Depositary Receipt (“ADR”) program

Paris (France) and Cambridge (Massachusetts, USA), April 19, 2024 – 07:00am CET – Biophytis SA
(Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage
biotechnology company specialized in the development of therapeutics for age-related diseases, today
annouces that it will change the ratio of its American Depositary Shares (the “ADSs”) to Biophytis
ordinary shares (the “Shares”) from one ADS representing 100 Shares, to one ADS representing 4,000
Shares (the “Ratio Change”). The effective date of the Ratio Change (the “Effective Date”) is expected
to be April 23, 2024.

Pursuant to the Ratio Change, as of the Effective Date, record holders who directly hold ADRs will be
required to exchange their existing ADRs for new ADRs on the basis of one new ADR for every 40 existing
ADRs surrendered. The Depositary will contact ADR holders and arrange for the exchange of their
existing ADRs for new ADRs. ADS beneficial holders who hold through an ADR holder intermediary need
not take any action in connection with the Ratio Change. For ADS holders, the Ratio Change will have
the same effect as a one-for-forty reverse ADS split. The ADSs will continue to be traded on The Nasdaq
Capital Market under the symbol “BPTS”.

No new Shares will be issued in connection with the Ratio Change and this Ratio Change does not change
the total number of Biophytis ordinary shares.

As a result of the Ratio Change, the trading price of the Company’s ADSs is expected to automatically
increase proportionally, but the Company can give no assurance that the ADS trading price following
the Ratio Change will be at least equal to the ADS trading price before the Ratio Change multiplied by
the new 40:1 ratio.



About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug
candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small
molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy),
respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The
company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are
listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary
Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information,
visit www.biophytis.com

Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all
statements that are not historical facts. In some cases, you can identify these forward-looking
statements by the use of words such as "outlook," "believes," "expects," "potential," "continues,"
"may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates,"
Press release

"anticipates" or the negative version of these words or other comparable words. Such forward-looking
statements are based on assumptions that Biophytis considers to be reasonable. However, there can
be no assurance that the statements contained in such forward-looking statements will be verified,
which are subject to various risks and uncertainties. The forward- looking statements contained in this
press release are also subject to risks not yet known to Biophytis or not currently considered material
by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or
results to differ materially from those indicated in these statements. Please also refer to the "Risk and
uncertainties the Company is to face» section from the Company’s 2023 Financial Report available on
BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as
well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no
obligation to publicly update or review any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as required by law.

Biophytis contacts

Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com

Media
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr – +33 6 38 31 90 50